Andy Wilcox is an independent researcher writing about viruses, pandemics, and public-health response. He is not a physician, and nothing here is medical advice — his work is the product of disciplined primary-source research, applying the same analytical approach he has used across 30+ years as a consultant, operating executive, and investor.
He holds an MBA from Duke University's Fuqua School of Business and is a licensed CPA and certified Project Management Professional (PMP) — a background built on evaluating evidence carefully and reasoning with data. His consulting career began at Ernst & Young, where he led business-process and systems-implementation projects for Fortune 500 clients including the pharmaceutical company Eli Lilly and the hospital network Partners HealthCare, giving him early exposure to how large healthcare and life-sciences organizations operate.
Since 2015 he has served on the Executive, Screening, and Due Diligence committees of Triangle Angel Partners, an angel fund that invests in life-sciences and high-tech companies alongside members who include physicians, PhDs, and career investors — its portfolio includes medical-technology ventures such as Deep Blue Medical and OrbitalRX. Evaluating early-stage companies means reading the underlying science critically, pressure-testing claims, and separating evidence from hype — the same habits he brings to this research. He is comfortable with data and probability, having built Monte Carlo forecasting models and led complex quantitative analysis, which shapes how he reads epidemiological data and study results rather than headlines.
His focus on viruses began during the COVID-19 pandemic, and it began personally. His aging parents were confined to their assisted-living facility, and watching the toll of that isolation led him to research its emotional impact on at-risk populations — which widened into a broader study of what triggers a pandemic, which public-health responses hold up under scrutiny, and how outbreaks ripple through economies and communities. Since 2020 he has read and summarized hundreds of articles and peer-reviewed studies and tracked every major variant wave, citing primary sources rather than aggregating other websites.
EbolaQuestions.com brings that same research practice to ebolaviruses and the broader filovirus family — among the most lethal and closely watched pathogens in public health. It's part of Virus Questions (virusquestions.com), a network he founded that also includes CoronavirusQuestions.com, HantavirusQuestions.com, and NorovirusQuestions.com. You can find him on LinkedIn at linkedin.com/in/andyswilcox.
Editorial Approach
Every factual claim on this site is drawn from authoritative primary sources — the CDC, WHO, FDA, and peer-reviewed scientific literature. Where scientific consensus exists, content reflects it. Where uncertainty exists, it is stated explicitly rather than papered over.
Four habits from that background show up on every Ebola page, and they are checkable:
- Read the label, not the summary. The claim that the approved antibody treatments are "not established" against Bundibugyo virus is quoted from the FDA prescribing information for Inmazeb and Ebanga, not paraphrased from news reports.
- Read the data file, not the chart. CDC's outbreak chart comparing 2014, 2018 and 2026 is fed by a public CSV; the history page tabulates it day by day, which the chart's own caption does not.
- Show the arithmetic. Where a number on this site is ours — a known-outcome fatality bound, a per-case cost — it is labelled "our calculation" with the inputs beside it, and the reasons it might be wrong.
- Verify every citation. In September 2026 every PubMed ID and DOI on the research page was re-checked; six were wrong and one referred to a paper that does not exist. They were fixed and logged on the corrections page.
His business and financial background is relevant on the economic impact page, where it is stated; it is not clinical expertise and is not presented as such anywhere on this site. For more detail on how content is sourced, reviewed, and corrected, see the How We Research page.
Medical Disclaimer
Contact
For corrections, questions about content, or to report a factual error, please use the contact page.
What this site's record shows
A method described in a paragraph is an assertion. These figures are computed from EbolaQuestions.com's own published data and change only when the pages do.
- Corrections logged on this site
- 15 (+1 network-wide)
- Risk figures with a published primary source
- 0 of 5 — the other 5 are shown as unavailable rather than estimated
- Surveillance confidence in the underlying Ebola data
- moderate — actively evolving situation
Read every correction, with what was published and what it says now →
See each Ebola figure beside its source and date →
Where this author's expertise ends
Andy Wilcox is not a physician, epidemiologist, or virologist. Nothing on EbolaQuestions.com can tell you whether a Ebola symptom, exposure, or test result means anything in your case — that is a clinical judgement this site is not qualified to make. Every health claim here traces to CDC, WHO, NIH, or peer-reviewed literature; where those are silent, this site is silent too. The full statement of what that boundary rules out, and what thirty years of verifying other people's claims does support, is on the network author page.